MichaelAnthonyDempseyMD

Endocrinology • Rockville, MD

Diabetes, Lipid Metabolism

Endocrine and Metabolic Consultants

Join to view full profile

Dr. Dempsey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dempsey's full profile

Already have an account?

Office
3200 Tower Oaks Blvd
Ste 250
Rockville, MD 20852
Phone+1 301-770-7373

Fax+1 301-770-7272

Summary

Dr. Michael Dempsey is an experienced endocrinologist based in Rockville, MD, with subspecialties in diabetes and lipid metabolism. He completed his medical education at Harvard Medical School, followed by an internal medicine internship and residency at George Washington University, and fellowships in Endocrinology, Diabetes, and Metabolism at Johns Hopkins University and Joslin Diabetes Center. He serves as the Endocrine Section Chair at Suburban Hospital and a Medical Staff Physician at Adventist Healthcare Shady Grove Medical Center. His expertise includes diabetes management and thyroid and metabolism disorders. Dr. Dempsey has contributed to patient education and published research on diabetes treatments. He has been recognized for his contributions with several awards, including the Compassionate Doctor Award and Top Doctors listings.

Education & Training

Joslin Diabetes CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1988 - 1989
Johns Hopkins UniversityFellowship, Endocrinology, Diabetes, and Metabolism, 1986 - 1988
George Washington UniversityResidency, Internal Medicine, 1984 - 1986
George Washington UniversityInternship, Internal Medicine, 1983 - 1984
Harvard Medical SchoolClass of 1983

Certifications & Licensure

MD State Medical License 1986 - 2026
DC State Medical License 1985 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Compassionate Doctor Award Vitals American Registry, 2011, 2016, 2018-2021
Top Doctors Endocrinology and Metabolism Castle Connolly, 2009-2021
Top Doctors Washingtonian Magazine, 2009-2021
Volunteer of the Year Community Ministries of Rockville, 2018
Fellow (FACP) American College of Physicians, 1991
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) Start of enrollment: 2008 Dec 10
Completed
Phase 3
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) Start of enrollment: 2010 Jun 01
Completed
Phase 3
EXCEL Clinical Trial Start of enrollment: 2010 Sep 29
Completed
Not Applicable
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) Start of enrollment: 2011 Apr 11
Completed
Phase 3
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients Start of enrollment: 2011 Nov 01
Completed
Phase 2
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin Start of enrollment: 2011 Dec 01
Completed
Phase 3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy Start of enrollment: 2011 Dec 01
Completed
Phase 3
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin Start of enrollment: 2012 Apr 01
Completed
Phase 3
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2012 May 01
Completed
Phase 3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy Start of enrollment: 2012 Aug 01
Completed
Phase 3
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus Start of enrollment: 2012 Sep 01
Completed
Phase 3
Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes Start of enrollment: 2013 Aug 26
Completed
Phase 3
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes Start of enrollment: 2014 Jan 01
Completed
Phase 3
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes Start of enrollment: 2014 May 01
Completed
Phase 3
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine Start of enrollment: 2015 Jan 01
Completed
Phase 3
Dose-ranging Study in Patients With Type 1 Diabetes Mellitus Start of enrollment: 2015 Jul 01
Completed
Phase 2
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes Start of enrollment: 2015 Sep 21
Completed
Phase 2
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes Start of enrollment: 2016 May 04
Completed
Phase 3
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone Start of enrollment: 2015 Sep 01
Completed
Phase 3
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients Start of enrollment: 2015 Dec 01
Completed
Phase 3
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes Start of enrollment: 2016 Jul 06
Completed
Phase 3
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin Start of enrollment: 2016 Nov 01
Completed
Phase 3
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus Start of enrollment: 2016 Dec 02
Completed
Phase 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Start of enrollment: 2017 Feb 02
Completed
Phase 3
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs Start of enrollment: 2017 Mar 13
Completed
Phase 3
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine Start of enrollment: 2017 Aug 02
Completed
Phase 3
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes Start of enrollment: 2017 Sep 19
Completed
Phase 3
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents Start of enrollment: 2017 Sep 15
Completed
Phase 3
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy Start of enrollment: 2017 Dec 01
Completed
Phase 3
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin Start of enrollment: 2017 Nov 27
Completed
Phase 3
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents Start of enrollment: 2018 Feb 20
Terminated
Phase 3
A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2018 Nov 15
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes.
Anuj Bhargava, Richard M Bergenstal, Mark L Warren, James R Thrasher, Michael A Dempsey
Diabetes Technology & Therapeutics. 2025-02-06
6 citations
Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Michael Dempsey, Michelle Mocarski, Jakob Langer, Barnaby Hunt
Endocrine Practice. 2018-10-11
4 citations
Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart ...
Michael Dempsey, Michelle Mocarski, Jakob Langer, Barnaby Hunt
Journal of Medical Economics. 2018-09-06

Other

Patient Education articles and videos
Michael Dempsey
http://www.thediabetesdoc.com/prediabetes

Committees

Member, AACE Public Impact Committee 2018 - Present
Board Member, Mid-Atlantic Regional Chapter AACE 2011 - Present
President, Mid-Atlantic Regional Chapter AACE 2018 - 2020
Committee member, AACE Underserved Population Committee 2016 - 2018
Vice-President, Mid-Atlantic Regional Chapter AACE 2016 - 2018
Committee Member, Institutional Review Board, Washington Adventist Health Care 2012 - 2017
Committee member, AACE Clinical Research Committee 2012 - 2015
Chair, Community Outreach Committee, Montgomery County Medical Society 2011 - 2012
Board Member, Montgomery County Medical Society 2011 - 2012
Steering Committee, Healthy Montgomery 2011 - 2012
Associate Editor, Montgomery Medicine 1999 - 2000
Assistant Editor, Montgomery Medicine 1998 - 1999

Research History

Clinical TrialsOver 150 Phase 2 and Phase 3 clinical trials as PI or sub-I since 1988. Research interests include diabetes, lipid disorders, CV disease and male hypogonadism. Please contact office for a copy of my full research CV.1998 - Present